Skip to main content

Advertisement

Table 1 Patient characteristics

From: Perioperative clinical and economic outcomes associated with replacing first-generation high molecular weight hydroxyethyl starch (Hextend®) with low molecular weight hydroxyethyl starch (Voluven®) at a large medical center

  2009 ( n= 2,098) 2010 ( n= 2,790) P value
Total N Mean or n SD or percentage Total N Mean or n SD or percentage
Age (yrs) (mean, SD) 2,098 58.1 15.4 2,790 58 15.6 0.8910
Female gender (n,%) 1,972 902 45.7 2,767 1,343 48.5 0.0574
Race (n,%) 1,966    2,762    0.7380
 White   1,454 74   2,043 74 0.9933
 Black   430 21.9   601 21.8 0.9266
 Nat. Amer   23 1.2   26 0.9 0.4444
 Asian   21 1.1   22 0.8 0.3322
 Other   35 1.8   65 2.4 0.1621
 Multiracial   3 0.2   5 0.2 1.0000
BMI (mean, SD) 1,884 29.6 7.3 2,639 29.5 7.3 0.9510
CAD preop (n,%) 1,383 721 52.1 1,839 1,016 55.2 0.0792
COPD preop (n,%) 1,383 83 6 1,839 116 6.3 0.7207
CABG preop (n,%) 1,383 9 0.7 1,839 12 0.7 0.9951
MI preop (n,%) 1,383 21 1.5 1,839 29 1.6 0.8942
Preop valve dz (n,%) 1,383 48 3.5 1,839 67 3.6 0.7938
Diabetes type I (n,%) 1,383 6 0.4 1,839 11 0.6 0.6274
Diabetes type II (n,%) 1,383 224 16.2 1,839 331 18 0.1799
Hypertension preop (n,%) 1,383 721 52.1 1,839 1,016 55.2 0.0792
Preop creatinine (mean, SD) 1,370 1 0.6 1,847 1.1 1.3 0.1725
  1. yrs, years; Nat. Amer, Native American; BMI, body mass index; h/o, history of; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; Preop valve dz, preoperative valve disease; CABG, coronary artery bypass graft; MI, myocardial infarction; DM, diabetes mellitus; preop, preoperative; SD, standard deviation.